Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.290
+0.150 (3.62%)
At close: Aug 21, 2026, 4:00 PM EDT
4.310
+0.020 (0.47%)
After-hours: Aug 21, 2026, 7:46 PM EDT
Ironwood Pharmaceuticals Employees
Ironwood Pharmaceuticals had 100 employees as of December 31, 2025. The number of employees decreased by 153 or -60.47% compared to the previous year.
Employees
100
Change (1Y)
-153
Growth (1Y)
-60.47%
Revenue / Employee
$3,893,160
Profits / Employee
$1,298,680
Market Cap
708.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | -153 | -60.47% |
| Dec 31, 2024 | 253 | -14 | -5.24% |
| Dec 31, 2023 | 267 | 48 | 21.92% |
| Dec 31, 2022 | 219 | 0 | - |
| Dec 31, 2021 | 219 | -13 | -5.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,461 |
| Tilray Brands | 3,595 |
| Amphastar Pharmaceuticals | 1,976 |
| Canopy Growth | 1,128 |
| Pacira BioSciences | 829 |
| Kamada | 462 |
| Glass House Brands | 426 |
| Collegium Pharmaceutical | 423 |
IRWD News
- 17 days ago - Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 17 days ago - Ironwood Pharmaceuticals Earnings release: Q2 2026 - Filings
- 17 days ago - Ironwood Pharmaceuticals Slides: Q2 2026 - Filings
- 17 days ago - Ironwood Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 17 days ago - Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Business Wire
- 24 days ago - Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call - Business Wire
- 5 weeks ago - Ironwood CMO Michael Shetzline to retire, Jeffrey Silber to succeed - TheFly
- 5 weeks ago - Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients - Business Wire